MorphoSys

EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

Retrieved on: 
Thursday, October 26, 2023
FSE, Anticipation, Clothing, Pharmaceutical industry, Tafasitamab, MorphoSys

Sales and Gross Margin, and Updates Financial Guidance for 2023

Key Points: 
  • Sales and Gross Margin, and Updates Financial Guidance for 2023
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S.
  • Sales and Gross Margin, and Updates Financial Guidance for 2023
    Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million)
    Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%
    Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin for Monjuvi U.S. net product sales to be approximately 75%
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) today reported preliminary Monjuvi® U.S. Net Product Sales and Gross Margin for the third quarter of 2023 and provided an update to its financial guidance for 2023.
  • Preliminary Gross Margin for Monjuvi U.S. Net Product Sales for Q3 2023 is 65%, due to the recognition of one-time write-offs for raw material used in the production of Monjuvi.

Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

Retrieved on: 
Wednesday, October 4, 2023
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Constellation, Bachelor of Science, PTC Therapeutics, University, University of London, Therapy, MorphoSys, South African Institute of Chartered Accountants, Cardiovascular disease, Parexel, Bristol Myers Squibb, Sale, Editas Medicine, PDE9, Inotek Pharmaceuticals, Novartis, Patient, Trustee, Risk, Imperial College London, Merck, Ca2+/calmodulin-dependent protein kinase II, Pharmaceutical industry

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.
  • Ms. Reeve brings to Cardurion more than 25 years of global financial leadership and board experience across pharmaceutical, medical device and biopharma companies.
  • As a seasoned life sciences executive with deep expertise in finance, capital markets and corporate strategy, Emma brings tremendous perspective to Cardurion’s Board,” said Michael E. Mendelsohn, M.D., Founder and Chairman of Cardurion.
  • “I am impressed with the bold and innovative approach Cardurion is taking to help patients suffering from and at risk for cardiovascular disease,” said Ms. Reeve.

Inari Appoints Lara Smith Weber as Chief Financial Officer

Retrieved on: 
Tuesday, September 19, 2023
IPO, BS, MorphoSys, Senior, Stanford University, Telecommunications, IMD, Food, MBA, Accounting, Lara, Booz Allen Hamilton, Master of Science, Corporate finance, CFO, Growth, Management, Telefónica Germany

CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- Inari today announced that Lara Smith Weber has been named chief financial officer, effective October 1. Smith Weber currently serves as CFO for ONWARD Medical, a medical technology company, and brings more than 20 years of experience in finance, accounting, and strategy for publicly traded life science and telecommunications entities in the US and Europe. 

Key Points: 
  • CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- Inari today announced that Lara Smith Weber has been named chief financial officer, effective October 1.
  • Lara is clearly the right financial leader to help manage this period of rapid growth," said Ponsi Trivisvavet, chief executive officer at Inari.
  • Smith Weber has also held leadership roles with Telefonica Germany and worked for Booz Allen Hamilton consulting firm.
  • "I am inspired by Inari's mission to make a meaningful impact on global sustainability and food supply by using cutting-edge technology," said Smith Weber.

EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Retrieved on: 
Saturday, September 16, 2023
Ruxolitinib, Peripheral T-cell lymphoma, MorphoSys, Half-life, Tafasitamab, Joint Planning and Development Office, Fast Track, FSE, Immunotherapy, B-cell lymphoma, ASCO, BET, Squamous-cell carcinoma, Endometrial cancer, American Society of Clinical Oncology, Patient, ARID1A, Lymphoma, Annual general meeting, FDA, EZH1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, EZH2, Pharmaceutical industry

The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.

Key Points: 
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.
  • The Fast Track designation in endometrial cancer was granted based on preclinical results and preliminary clinical data from an ongoing Phase 1/2 study.
  • “Receiving Fast Track designation from the FDA for tulmimetostat in ARID1A-mutated endometrial cancer underscores this investigational therapy’s potential in a patient population with limited treatment options,” said Tim Demuth, M.D., Ph.D., MorphoSys Chief Research and Development Officer.
  • Pelabresib, an investigational BET inhibitor, received Fast Track designation for myelofibrosis in 2018, and tafasitamab, a CD19-targeting immunotherapy, received this designation for relapsed or refractory diffuse large B-cell lymphoma in 2014.

HOOKIPA Announces Executive Leadership Change

Retrieved on: 
Wednesday, September 13, 2023
MorphoSys, Internal medicine, Hookipa (board game), Roche, Arenavirus, CMO, Development, Patient, Pharmaceutical industry, Novartis

Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete.

Key Points: 
  • Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete.
  • During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.
  • Dr. Peters is a seasoned executive with deep experience in bringing new therapies to patients.
  • Prior, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany and spent 12 years in leadership positions at Novartis Oncology.

Sjogren's Syndrome Drug Pipeline Research Report 2023: Comprehensive Exploration of 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, September 4, 2023
Health, Pharmaceutical, Partnership, MorphoSys, TNF, ADCC, Survival, Clinical trial, NDA, Sjögren syndrome, Inflammation, Discovery, Monocyte, Novartis, Sjögren, BAFF-R, Horizon, CD40L, BAFF, News, FC, Family, B cell, III, Pharmaceutical industry, Vaccine, Phase

The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.

Key Points: 
  • The "Sjogren's syndrome - Pipeline Insight, 2023" report offers a comprehensive exploration of the landscape, encompassing over 20 companies and more than 25 pipeline drugs within the realm of Sjogren's syndrome.
  • The report not only sheds light on active pipeline products but also presents insights into inactive pipeline products within this domain.
  • Within this comprehensive report lies a detailed portrayal of the current landscape and the potential growth prospects within this therapeutic indication.
  • With an overview of Sjogren's syndrome treatment guidelines and disease overview, the report constructs a thorough picture of the Sjogren's syndrome pipeline landscape.

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Operating cost, Ruxolitinib, SG, Tafasitamab, DLBCL, G&A, Patient, Administration, Research and development, R, Asset, Indolent lymphoma, Fine chemical, Cryptocurrency, Assurance services, Bookkeeping, Music, MorphoSys, Incyte

In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.

Key Points: 
  • In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.
  • Full Year 2023 Financial Guidance:
    100% of Monjuvi U.S. net product sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • Additional information related to 2023 Financial Guidance:
    Tremfya® royalties will continue to be recorded as revenue without any cost of sales in MorphoSys’ income statement.
  • MorphoSys Group Key Figures (IFRS, end of the second quarter: June 30, 2023)

EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Rituximab, Ruxolitinib, MorphoSys, European Hematology Association, Conference call, Hydroxycarbamide, JAK, ICML, American Society of Clinical Oncology, Lymphoma, Lenalidomide, Cancer, FSE, Incyte, ASCO, BET, Publication, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, EHA, Annual general meeting, Webcast, Society, Conference, Safety, Nursing, Pharmaceutical industry, Beauty salon, Tafasitamab

Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.

Key Points: 
  • Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.
  • The MorphoSys AG Annual General Meeting on May 17, 2023 re-elected Mr. George Golumbeski, Ph.D., and Mr. Michael Brosnan to the Company’s Supervisory Board.
  • Events After the End of the Second Quarter of 2023:
    On August 1, 2023, Incyte announced the full enrollment of the Phase 3 study inMIND.
  • Total revenues for the second quarter 2023 were € 53.2 million compared to € 59.4 million for the same period in 2022.

EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Retrieved on: 
Thursday, August 3, 2023
Webcast, Management, MorphoSys, FSE, Q&A, Conference, CEST, EDT, BST, Clothing, Video game

Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Key Points: 
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on August 10, 2023, at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the second quarter and first half 2023 and provide an outlook for 2023.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

Xencor Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Janssen, G&A, Atopic dermatitis, CLDN6, European Society for Medical Oncology, Congress, Patient, Investment, STEAP1, R, NK, NMOSD, European Congress of Mathematics, Manuscript, Vir, EULAR, IND, Safety, CD3, Amgen, ESMO, Cancer, AMG, Antibody, Psoriasis, Ovarian cancer, Pembrolizumab, PARP, Renal cell carcinoma, Progression-free survival, CD28, Telephone, Part, Janssen Pharmaceuticals, Notifiable disease, Cytokine, Neuromyelitis optica spectrum disorder, European Society of Gynaecological Oncology, Tumor microenvironment, Vaccine, Pharmaceutical industry, Cryptocurrency, EU, Alexion, Ravulizumab, MorphoSys, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.
  • In the second quarter of 2023, Xencor earned $11.2 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Decreased net loss in the second quarter of 2023 compared to 2022 is primarily due to additional income and interest earned.
  • ET (1:30 p.m. PT) to discuss the second quarter 2023 financial results and provide a corporate update.